Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 398  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission


This article has been cited by
1A novel approach to sterile pharmaceutical freeze-drying
Christopher Lee Albert Cherry,Huw Millward,Rose Cooper,John Landon
Pharmaceutical Development and Technology.2014;19(1)73
[DOI]
2A novel approach to sterile pharmaceutical freeze-drying
Anthea Hucklesby
Pharmaceutical Development and Technology.2018;19(1)223
[DOI]
3“Getting ready for the adult world”: how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being
Hamish W. Y. Wan,Kate A. Carey,Arlene D’Silva,Nadine A. Kasparian,Michelle A. Farrar
Orphanet Journal of Rare Diseases.2019;14(1)223
[DOI]
4Product lifecycle management through patents and regulatory strategies
Vandana Prajapati,Swagat Tripathy,Harish Dureja
Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing.2013;13(3)171
[DOI]
5Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
Pengfei Jiang,Rajesh Mukthavavam,Ying Chao,Ila Bharati,Valentina Fogal,Sandra Pastorino,Xiuli Cong,Natsuko Nomura,Matt Gallagher,Taher Abbasi,Shireen Vali,Sandeep C Pingle,Milan Makale,Santosh Kesari
Journal of Translational Medicine.2014;12(1)13
[DOI]
6Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs
Deeplina Das,Arun Goyal
Journal of Translational Medicine.2014;12(1)367
[DOI]
7WITHDRAWN: “Good news is not always a positive market signal”—Investors activity around orphan drug designation
Tiran Rothman
Economics Letters.2017;12(1)367
[DOI]
8A survey of critical care pharmacists to patient ratios and practice characteristics in intensive care units
Andrea S. Newsome,Susan E. Smith,Timothy W. Jones,Ashley Taylor,Megan A. Van Berkel,Marina Rabinovich
Journal of the American College of Clinical Pharmacy.2020;3(1)68
[DOI]
9The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America
Renée J.G. Arnold,Lida Bighash,Alejandro Bryón Nieto,Gabriela Tannus Branco de Araújo,Juan Gabriel Gay-Molina,Federico Augustovski
F1000Research.2015;4(1)57
[DOI]
10The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US/EU and in Latin America
Dev Bukhsh Singh
F1000Research.2017;4(1)299
[DOI]
11Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL)
Lieven Annemans,Ségolène Aymé,Yann Le Cam,Karen Facey,Penilla Gunther,Elena Nicod,Michele Reni,Jean-Louis Roux,Michael Schlander,David Taylor,Carlo Tomino,Josep Torrent-Farnell,Sheela Upadhyaya,Adam Hutchings,Lugdivine Le Dez
Orphanet Journal of Rare Diseases.2017;12(1)299
[DOI]
12Orphan drugs: the regulatory environment
Pedro Franco
Drug Discovery Today.2013;18(3-4)163
[DOI]
13Estimating the budget impact of orphan drugs in Sweden and France 2013–2020
Adam Hutchings,Carina Schey,Richard Dutton,Felix Achana,Karolina Antonov
Orphanet Journal of Rare Diseases.2014;9(1)22
[DOI]
14Effectiveness, safety and costs of orphan drugs: an evidence-based review
Igho J Onakpoya,Elizabeth A Spencer,Matthew J Thompson,Carl J Heneghan
BMJ Open.2015;5(6)e007199
[DOI]
15New concepts on the therapeutic control of complement anaphylatoxin receptors
Owen A. Hawksworth,Xaria X. Li,Liam G. Coulthard,Ernst J. Wolvetang,Trent M. Woodruff
Molecular Immunology.2017;89(6)36
[DOI]
16From Rare to Neglected Diseases: A Sustainable and Inclusive Healthcare Perspective for Reframing the Orphan Drugs Issue
Marialuisa Saviano,Sergio Barile,Francesco Caputo,Mattia Lettieri,Stefania Zanda
Sustainability.2019;11(5)1289
[DOI]
17Promoting innovation and access to quality, safe, efficacious, and affordable medicines for children: A China approach on the 69th World Health Assembly
Lingli Zhang,Bo Li,Zhanqiang Liu,Mengtao Li,Hong Zheng,Yang Sun
Journal of Evidence-Based Medicine.2017;10(2)70
[DOI]
18When Everyone Is an Orphan: Against Adopting a U.S.-Styled Orphan Drug Policy in Canada
Matthew Herder
Accountability in Research.2013;20(4)227
[DOI]
19Optimizing efficacy of mucosal vaccines
Ayman Gebril,Manal Alsaadi,Reinaldo Acevedo,Alexander B Mullen,Valerie A Ferro
Expert Review of Vaccines.2012;11(9)1139
[DOI]
20Optimizing efficacy of mucosal vaccines
Thomas Friedli,Daniel Bellm
Expert Review of Vaccines.2013;11(9)77
[DOI]
21Challenges in orphan drug development and regulatory policy in China
Alice Cheng,Zhi Xie
Orphanet Journal of Rare Diseases.2017;12(1)77
[DOI]
22Using phase II data for the analysis of phase III studies: An application in rare diseases
Simon Wandel,Beat Neuenschwander,Christian Röver,Tim Friede
Clinical Trials.2017;14(3)277
[DOI]
23Lipid Control in the Modern Era
Richard V. Milani,Carl J. Lavie
Journal of the American College of Cardiology.2013;62(23)2185
[DOI]
24Lipid Control in the Modern Era
B. Andraka-Christou
Journal of the American College of Cardiology.2016;126(23)15
[DOI]
25Lipid Control in the Modern Era
Timothy M. Cox
Journal of the American College of Cardiology.2011;5(23)49
[DOI]
26Factors That Affect the Acquisition of Reward Premiums for Promotion of Innovative Drug Discovery in Japan
Shoyo Shibata,Ryotaro Uemura,Takeshi Suzuki
Therapeutic Innovation & Regulatory Science.2016;50(1)56
[DOI]
27Industry Perspective of Pediatric Drug Development in the United States: Involvement of the European Union Countries
Taku Onishi,Katsura Tsukamoto,Naoki Matsumaru,Takashi Waki
Therapeutic Innovation & Regulatory Science.2018;52(1)49
[DOI]
28Hematopoietic Stem Cell Gene Therapy for Inherited Monogenic Diseases and Its Implications for Future Gene Therapy Trials in Turke
Fatima Aerts-Kaya,Gülen Güney Esken,Özgür Dogus Erol
Trakya University Journal of Natural Sciences.2019;52(1)49
[DOI]
29In Vitro Screening for Drug Repositioning
Graeme F. Wilkinson,Kevin Pritchard
Journal of Biomolecular Screening.2015;20(2)167
[DOI]
30A review of the progress and pitfalls of FDA policy process: Planning a pathway for pharmaceutical interventions for hearing loss development
Tanisha L. Hammill
Hearing Research.2017;349(2)172
[DOI]
31Quantifying the persisting orphan-drug shortage public health crisis in the United States
Szymon Jaroslawski,Chiraz Azaiez,Daria Korchagina,Mondher Toumi
Journal of Market Access & Health Policy.2017;5(1)1269473
[DOI]
32A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy
Jiayi Huang,Jian L. Campian,Amit D. Gujar,David D. Tran,A. Craig Lockhart,Todd A. DeWees,Christina I. Tsien,Albert H. Kim
Journal of Neuro-Oncology.2016;128(2)259
[DOI]
33The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases
Kristina Sachs-Barrable,Jocelyn Conway,Pavel Gershkovich,Fady Ibrahim,Kishor M. Wasan
Drug Development and Industrial Pharmacy.2014;40(11)1429
[DOI]
34Accelerated Access to Medicines: An Ethical Analysis
Jessica Pace,Narcyz Ghinea,Ian Kerridge,Wendy Lipworth
Therapeutic Innovation & Regulatory Science.2017;51(2)157
[DOI]
35Orphan Drugs and Potential Novel Approaches for Therapies of ß-Thalassemia: Current Status and Future Expectations
Alessia Finotti,Monica Borgatti,Nicoletta Bianchi,Cristina Zuccato,Ilaria Lampronti,Roberto Gambari
Expert Opinion on Orphan Drugs.2016;4(3)299
[DOI]
36Finding a Cure: Incentivizing Partnerships Between Disease Advocacy Groups and Academic and Commercial Researchers
Anne Readel
SSRN Electronic Journal.2013;4(3)299
[DOI]
37Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries
Todd Gammie,Christine Y. Lu,Zaheer Ud-Din Babar,Silvio Garattini
PLOS ONE.2015;10(10)e0140002
[DOI]
38Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Kavisha Jayasundara,Aidan Hollis,Murray Krahn,Muhammad Mamdani,Jeffrey S. Hoch,Paul Grootendorst
Orphanet Journal of Rare Diseases.2019;14(1)e0140002
[DOI]
39A Cross-Sectional Study to Evaluate the Awareness and Attitudes of Physicians Towards Reducing the Cost of Prescription Drugs, Mumbai
Gauri Billa,Karan Thakkar,Sarita Jaiswar,Dinesh Dhodi
Applied Health Economics and Health Policy.2014;12(2)125
[DOI]
40Pain in an era of armed conflicts: Prevention and treatment for warfighters and civilian casualties
E. George,I. Elman,L. Becerra,Sheri Berg,D. Borsook
Progress in Neurobiology.2016;141(2)25
[DOI]
41Static and Dynamic Properties of Fluorinated 4-Aryl-1,5-Benzodiazepinones
Olga Martín,Marta Pérez-Torralba,M. Ángeles García,Rosa M. Claramunt,M. Carmen Torralba,M. Rosario Torres,Ibon Alkorta,José Elguero
ChemistrySelect.2016;1(4)861
[DOI]
42Benefits of investment into modern medicines in Central–Eastern European countries
András Inotai,Guenka Petrova,Dinko Vitezic,Zoltán Kaló
Expert Review of Pharmacoeconomics & Outcomes Research.2014;14(1)71
[DOI]
43Notable Differences in Drug Lag Between Korea and Japan of New Drugs Between 2009 and 2017
Sang-Won Lee,So-Hee Park,Inmyung Song,Yunha Noh,Hyekyung Park,Dongmun Ha,Ju-Young Shin
Therapeutic Innovation & Regulatory Science.2019;14(1)216847901983846
[DOI]
44Regulatory issues for orphan medicines: A review
Maria Luísa Bouwman,João José Simões Sousa,Maria Eugénia Tavares Pina
Health Policy and Technology.2020;9(1)115
[DOI]
45What does mainstream media say about enzyme replacement therapies?
Stephanie Skinner,Katrina Assen,Ian Mitchell
Paediatrics & Child Health.2018;23(6)e117
[DOI]
46Insights into the pharmaceuticals and mechanisms of neurological orphan diseases: Current Status and future expectations
Teodorico C. Ramalho,Alexandre A. de Castro,Tássia S. Tavares,Maria C. Silva,Daniela R. Silva,Pedro H. Cesar,Lucas A. Santos,Elaine F.F. da Cunha,Eugenie Nepovimova,Kamil Kuca
Progress in Neurobiology.2018;169(6)135
[DOI]
47Financing drug discovery for orphan diseases
David E. Fagnan,Austin A. Gromatzky,Roger M. Stein,Jose-Maria Fernandez,Andrew W. Lo
Drug Discovery Today.2014;19(5)533
[DOI]
48Providing Medical Information for Orphan Drugs
Sean Turbeville,David A. Wells,Carl S. Hornfeldt
Drug Information Journal.2012;46(1)88
[DOI]
49A Single-use Strategy to Enable Manufacturing of Affordable Biologics
Renaud Jacquemart,Melissa Vandersluis,Mochao Zhao,Karan Sukhija,Navneet Sidhu,Jim Stout
Computational and Structural Biotechnology Journal.2016;14(1)309
[DOI]
50Orphan drugs: trends and issues in drug development
Proteesh Rana,Shalini Chawla
Journal of Basic and Clinical Physiology and Pharmacology.2018;29(5)437
[DOI]
51Orphan/rare drug discovery through drug repositioning
Ramaiah Muthyala
Drug Discovery Today: Therapeutic Strategies.2011;8(3-4)71
[DOI]
52Factors influencing the difference between forecasted and actual drug sales volumes under the price–volume agreement in South Korea
Sun-Young Park,Euna Han,Jini Kim,Eui-Kyung Lee
Health Policy.2016;120(8)867
[DOI]
53Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
Joachim Y. Doua,Jean-Pierre Van Geertruyden
Tropical Medicine & International Health.2014;19(1)23
[DOI]
54Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children
Stephen J. Balevic,Michael Cohen-Wolkowiez
The Journal of Clinical Pharmacology.2018;58(1)S58
[DOI]
55Cultural, geographical and ethical questions when looking to enroll pediatric patients in rare disease clinical trials
Stefan Anzelewicz,Hanna Garnier,Arun Rangaswami,Piotr Czauderna
Expert Opinion on Orphan Drugs.2017;5(8)613
[DOI]
56Relating business model innovations and innovation cascades: the case of biotechnology
Jorge Niosi,Maureen McKelvey
Journal of Evolutionary Economics.2018;28(5)1081
[DOI]
57The 13th Round: Article 39(3) TRIPS and the struggle over “Unfair Commercial Use”
Gabriele Spina Alì
The Journal of World Intellectual Property.2018;21(3-4)201
[DOI]
58Design of a framework for the deployment of collaborative independent rare disease-centric registries: Gaucher disease registry model
Matthew I. Bellgard,Kathryn R. Napier,Alan H. Bittles,Jeffrey Szer,Sue Fletcher,Nikolajs Zeps,Adam A. Hunter,Jack Goldblatt
Blood Cells, Molecules, and Diseases.2018;68(3-4)232
[DOI]
59Exploring different approaches to improve the success of drug discovery and development projects: a review
Geoffrey Kabue Kiriiri,Peter Mbugua Njogu,Alex Njoroge Mwangi
Future Journal of Pharmaceutical Sciences.2020;6(1)232
[DOI]
60The value of a health insurance database to conduct pharmacoepidemiological studies in oncology
Cécile Conte,Charlotte Vaysse,Pauline Bosco,Pernelle Noize,Annie Fourrier-Reglat,Fabien Despas,Maryse Lapeyre-Mestre
Therapies.2019;74(2)279
[DOI]
  Feedback 
  Subscribe 
  Advertise 

Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal